Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373587 | 0.93 | SMN1; SMN2 (0.46) | CNR1ALPLALDH1A1SMN1; SMN2 | |
| SCHEMBL12373568 | 0.90 | POLB (0.44) | ALPLGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL12373704 | 0.90 | CASP1 (0.45) | ALPLSMN1; SMN2 | |
| SCHEMBL12373527 | 0.87 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12373638 | 0.86 | LMNA (0.46) | ALPLS1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12373753 | 0.86 | ALPL (0.42) | ALPLALDH1A1SMN1; SMN2 | |
| SCHEMBL12373560 | 0.86 | SMN1; SMN2 (0.47) | ALPLGAAPKMSMN1; SMN2 | |
| SCHEMBL4119410 | 0.85 | CNR1 (0.47) | MMP7CNR1S1PR1ALDH1A1 | |
| SCHEMBL12373552 | 0.85 | PGR (0.44) | CNR1ALPLS1PR1GAAALDH1A1 | |
| SCHEMBL12373489 | 0.85 | LMNA (0.43) | CNR1S1PR1ALDH1A1MAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | MMP7 3408/4885CNR1 17/4885ALPL 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.